An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
Latest Information Update: 11 Sep 2023
At a glance
- Drugs Cemdisiran (Primary) ; Pozelimab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 11 Sep 2023 New trial record